Recent data from CWCI and WCRI, plus clinical concerns.
Recent data from CWCI and WCRI, plus clinical concerns.
The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.
As the market grows, it becomes necessary to understand efficacy, costs, and alternatives.
As opioid prescribing continues to decline, more nuanced and population-specific drug trends emerge as cost drivers.
Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.
Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.
Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.
A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.
The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.
